E. coli nitroreductase/CB1954: In vitro studies into a potential system for feline cancer gene therapy

Veterinary Journal

Volumn 161, Issue 3, 2001, Pages 269-279

  Blackwood, L ^a   O'Shaughnessy, P J ^a   Reid, S W J ^a   Argyle, D J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Feline; Gene therapy; Nitroreductase; Prodrug activation

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; NITROREDUCTASE; PRODRUG; THYROGLOBULIN;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CAT; CAT DISEASE; CELL TYPE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CYTOTOXICITY; ESCHERICHIA COLI; GENE THERAPY; IN VITRO STUDY; NONHUMAN; RAT; THYROID DISEASE;

ANIMALIA; ESCHERICHIA COLI; FELIDAE; FELIS CATUS;

EID: 0034995204     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1053/tvjl.2000.0557     Document Type: Article

References (34)

1. AMBESI-IMPIOMBATO, F. S., PARKS, L. A. & COON, H. G. (1980). Culture of hormone-dependent functional epithelial cells from rat thyroids. Proceedings of the National Academy of Sciences of the United States of America 77, 3455-59.
2. ANLEZARK, G. M., MELTON, R. G., SHERWOOD, R. F., COLES, B., FRIEDLOS, F. & KNOX, R. J. (1992). The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification & properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochemical Pharmacology 44, 2289-95.
3. ANLEZARK, G. M., MELTON, R. G., SHERWOOD, R. F., WILSON, W. R., DENNY, W. A., PALMER, B. D., KNOX, R. J., FRIEDLOS, F. & WILLIAMS, A. (1995). Bioactivation of dinitrobenzamide mustards by an E. coli B nitrore-ductase. Biochemical Pharmacology 50, 609-18.
4. BAILEY, S. M. & HART, I. R. (1997). Nitroreductase activation of CB 1954 - an alternative 'suicide' gene system. Gene Therapy 4, 80-1.
5. BAILEY, S. M., KNOX, R. J., HOBBS, S. M., JENKINS, T. C., MAUGER, A. B., MELTON, R. G., BURKE, P. J., CONNORS, T. A. & HART, I. R. (1996). Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy. Gene Therapy 3, 1143-50.
6. BLACKWOOD, L. (2000). Transcriptional Targeting of Gene Therapy in the Hyperthyroid Cat: Preliminary Investigations. University of Glasgow. PhD.
7. BOSHART, M., KLUPPEL, M., SCHMIDT, A., SCHUTZ, G. & LUCKOW, B. (1992). Reporter constructs with low background activity utilizing the cat gene. Gene 110, 129-30.
8. BRIDGEWATER, J. A., SPRINGER, C. J., KNOX, R. J., MINTON, N. P., MICHAEL, N. P. & COLLINS, M. K. (1995). Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. European Journal of Cancer 31A, 2362-70.
9. BRIDGEWATER, J. A., KNOX, R. J., PITTS, J. D., COLLINS, M. K. & SPRINGER, C. J. (1997). The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Human Gene Therapy 8, 709-17.
10. CLARK, A. J., IWOBI, M., CUI, W., CROMPTON, M., HAROLD, G., HOBBS, S., KAMALATI, T., KNOX, R., NEIL, C., YULL, F. & GUSTERSON, B. (1997). Selective cell ablation in transgenic mice expression E. coli nitroreductase. Gene Therapy 4, 101-10.
11. COBB, L. M., CONNORS, T. A., ELSON, L. A., KHAN, A. H., MITCHLEY, B. C., ROSS, W. C. & WHISSON, M. E. (1969). 2,4-dinitro-5-ethyleneiminobenzamide (CB1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochemical Pharmacology 18, 1519-27.
12. CRANDELL, R. A., FABRICANT, C. G. & NELSON-REES, W. A. (1973). Development, characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK). In Vitro 9, 176-85.
13. CUI, W., GUSTERSON, B. & CLARK, A. J. (1999). Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway. Gene Therapy 6, 764-70.
14. DEONARAIN, M. P., SPOONER, R. A. & EPENETOS, A. A. (1995). Genetic delivery of enzymes for cancer therapy. Gene Therapy 2, 235-44.
15. DRABEK, D., GUY, J., CRAIG, R. & GROSVELD, F. (1997). The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Therapy 4, 93-100.
16. FRIEDLOS, F. & KNOX, R. J. (1992). Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system. Biochemical Pharmacology 44, 631-35.
17. FRIEDLOS, F., BIGGS, P. J., ABRAHAMSON, J. A. & KNOX, R. J. (1992). Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity. Biochemical Pharmacology 44, 1739-43.
18. FRIEDLOS, F., COURT, S., FORD, M., DENNY, W. A. & SPRINGER, C. (1998). Gene-directed enzyme pro-drug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Therapy 5, 105-12.
19. GREEN, N. K., YOUNG, D. J., NEOPTOLEMOS, J. P., FRIEDLOS, F., KNOX, R. J., SPRINGER, C. J., ANLEZARK, G. M., MICHAEL, N. P., MELTON, R. G., FORD, M. J., YOUNG, L.S., KERR, J. K. & SEARLE, P. F. (1997a). Sensitization of colorectal and pancreatic cancer cell lines to the pro-drug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Therapy 4, 229-38.
20. GREEN, N. K., YOUNG, D. J., Young, L. S., Kerr, D. J., NEOPTOLEMOS, J.P. & SEARLE, P.F. (1997b). Gene therapy for pancreatic cancer: in vivo killing of tumour cells expressing E. coli nitroreductase following administration of the prodrug CB1954: Gut 41, A188.
21. HARVEY, H. J., MACEWEN, E. G. & HAYES, A. A. (1977). Neurotoxicosis associated with use of 5-fluorouracil in five dogs and one cat. Journal of the American Veterinary Medical Association 171, 277-78.
22. KNOX, R. J., FRIEDLOS, F., JARMAN, M., DAVIES, L. C., GODDARD, P., ANLEZARK, G. M., MELTON, R. G. & SHERWOOD, R. F. (1995). Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochemical Pharmacology 49, 1641-47.
23. KNOX, R. J., FRIEDLOS, F., JARMAN, M. & ROBERTS, J. J. (1988b). A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochemical Pharmacology 37, 4661-69.
24. KNOX, R. J., FRIEDLOS, F., SHERWOOD, R. F., MELTON, R. G. & ANLEZARK, G. M. (1992). The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) - II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochemical Pharmacology 44, 2297-301.
25. KNOX, R. J., BOLAND, M. P., FRIEDLOS, F., COLES, B., SOUTHAN, C. & ROBERTS, J. J. (1988a). The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochemical Pharmacology 37, 4671-77.
26. KOZAK, M. (1989). The scanning model for translation: an update. Journal of Cell Biology 108, 229-41.
27. KOZAK, M. (1999). Initiation of translation in prokaryotes and eukaryotes. Gene 234, 187-208.
28. MCNEISH, I. A., GILLIGAN, M. G., GREEN, N. K., ROBERTS, S. M., KERR, J. K., FRIEDLOS, F., SPRINGER, C. J. & SEARLE, P. F. (1998). Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954. British Journal of Cancer 78, A155. (Abstract)
29. MICHAEL, N. P., BREHM, J. K., ANLEZARK, G. M. & MINTON, N. P. (1994). Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12. FEMS Microbiology Letters 124, 195-202.
30. OWENS, J. G., NASISSE, M. P., TADEPALLI, S. M. & DORMAN, D. C. (1996). Pharmacokinetics of acyclovir in the cat. Journal of Veterinary Pharmacology and Therapeutics 19, 488-90.
31. SEARLE, P. F., WEEDON, S. J., MCNEISH, I. A., GILLIGAN, M. G., FORD, M. J., FRIEDLOS, F., SPRINGER, C. J., YOUNG, L. S. & KERR, D. J. (1997). Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene. Cancer Gene Therapy 5, 304.
32. SERRANO, M., LIN, A. W., MCCURRACH, M. E., BEACH, D. & LOWE, S. W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
33. SUNTERS, A., BAER, J. & BAGSHAWE, K. D. (1991). Cytotoxicity and activation of CB1954 in a human tumour cell line. Biochemical Pharmacology 41, 1293-98.
34. WORKMAN, P., WHITE, R.A. & TALBOT, K. (1986). CB 1954 revisited. I. Disposition kinetics and metabolism. Cancer Chemotherapy and Pharmacology 16, 1-8.